Results Healthcare and Harel Consulting sign Cooperation Agreement to Facilitate Licensing in Emerging Markets
Results Healthcare, a healthcare advisory specialist that is part of the Results International Group, and Harel Consulting, a US-based business development consultancy with proprietary ties to leading pharmaceutical companies across the emerging markets, have signed a Cooperation Agreement.
According to the terms of the agreement, Results Healthcare will leverage its knowledge and relationships in the pharmaceutical and medical device sectors, particularly in Europe, to assist in identifying innovative companies that may become licensors for Harel Consulting’s Emerging Markets clients. Once the licensors are identified, the two companies may also work together to consummate the licensing deals.
Harel Consulting is led by Jacob Harel, a seasoned pharmaceutical executive with over 25 years of experience in the industry. Prior to founding Harel Consulting, he most recently served as Head of Corporate Business Development at Merck & Co., during which time he structured and negotiated a variety of deals around the globe and especially in Emerging Markets.
Kevin Bottomley, Managing Director at Results Healthcare commented on the agreement: “We are very pleased to have this opportunity to work with Harel Consulting. Jacob’s background enables him to see Emerging Markets opportunities from a developed world perspective. We believe that together we are well positioned to find the right opportunities for our clients in these markets.”
Jacob Harel, founder of Harel Consulting added: “Results Healthcare has an outstanding reputation for its knowledge and expertise in the pharmaceutical and medical devices sectors. Results Healthcare is well-suited to help us find, facilitate and execute licensing deals for our clients in Latin America, Eastern Europe, Middle East, Asia Pacific and Africa. We look forward to a fruitful collaboration.”
These future licensing deals are expected to bring more therapeutic choices to millions of patients in the Emerging Markets. Results Healthcare and Harel Consulting indicated that they are proud to make a contribution to the improvement of patients' health in these markets.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance